Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
NCT ID: NCT07010250
Last Updated: 2025-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
146 participants
OBSERVATIONAL
2025-06-02
2029-06-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers for the Progression of IgA Nephropathy
NCT02529722
Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
NCT03698071
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
NCT02257866
Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy
NCT02526966
Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN)
NCT07295808
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ANCA Associated Vasculitis
Case
No interventions assigned to this group
Extramembranous Glomerulopathy
Control
No interventions assigned to this group
Nephrotic Syndrome, Minimal Change
Control
No interventions assigned to this group
Interstitial Nephritis
Control
No interventions assigned to this group
IgA Nephropathy
Control
No interventions assigned to this group
Segmental Hyalinosis
Control
No interventions assigned to this group
Diabetic Nephropathy
Control
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 ans ≥ Age ≤ 90 ans
* Affiliation to french health insurance
* Patient having given consent
For the ANCA vasculitis group:
• Diagnosis of ANCA vasculitis retained on renal biopsy with ANCA anti-proteinase 3 (PR3) or ANCA anti-myeloperoxidase (MPO)
For the control groups:
• Diagnosis retained after the renal biopsy
* Interstitial Nephritis
* Or glomerular nephropathy such as minimal change nephropathy
* Or Segmental hyalinosis in itscollapsing form
* Or Extramembranous Glomerulopathy,
* Or glomerulopathy with mesangial IgA deposits
* Or diabetic nephropathy.
Exclusion Criteria
* Patient on dialysis (hemodialysis or peritoneal dialysis)
* Patient under legal protection, guardianship or curatorship
* Pregnancy or breastfeeding
* Enrollement in an interventional study except studies relating to ANCA vasculitis and nephropathy with mesangial IgA deposits.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, France
OTHER_GOV
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
National Research Agency, France
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marine LIVROZET
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Georges-Pompidou European Hospital, AP-HP
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRTS-21-0009
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
APHP211383
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.